A Phase 3 interventional study of NPC-07 for oral administration in Malignant Glioma, sponsored by Nobelpharma. Completed at 3 sites in Japan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-04-27.
Sponsored by Nobelpharma · Phase 3, Interventional, and Diagnostic
The aim of the present Phase III study is to assess the positive predictive value of NPC-07 (5-aminolevulinic acid hydrochloride) induced tissue fluorescence, safety and pharmacokinetics following a single dose of NPC-07 orally, at a dose of 20mg/kg/body weight, 3 hours prior to induction of anaesthesia for surgery of patients with newly or recurrent malignant glioma (WHO grades III/IV).
Positive predictive value will be confirmed by percentage of patients showing positive tumor cell identification in all biopsies taken from areas of strong and weak fluorescence. This study will be divided into two stages. After reviewing of the result of safety and pharmacokinetics of NPC-07 in small number of subjects by independent safety monitoring committee, more subjects will receive NPC-07 in Step II.
1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.
This study's enrollment of 45 is above the median of 32 across 1,065 interventional studies indexed under Glioma.
Browse Glioma studies →Nobelpharma is the lead sponsor of 34 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single administration of NPC-07 at a dose of 20mg/kg body weight
Drug: NPC-07 for oral administration
NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
Also known as: 5-ALA, 5-aminolevulic acid hydrochloride
Positive predictive value of tissue fluorescence
Positive predictive value of tissue fluorescence defined as the percentage of patients showing positive tumor cell identification in all 6 biopsies taken from areas of strong and weak fluorescence.
Time frame: 1 day
Quality of fluorescent tissue
Quality of fluorescent tissue by the judgement of the investigator
Time frame: 1 day
Positive predictive value of tissue fluorescence in each biopsy tissue sample
Positive predictive value of tissue fluorescence at the biopsy level defined as the number of tumor positive biopsies among all biopsies taken from areas of strong and weak fluorescence.
Time frame: 1 day
Percentage of patients without residual tumor
Percentage of patients without residual tumor in the MRI within 72 hours after surgery
Time frame: 3 days
Positive predictive value of non-fluorescent tissue at the biopsy level
Positive predictive value of tissue fluorescence at the biopsy level defined as the number of tumor positive biopsies among the non-fluorescent tissue adjacent to fluorescent tissue areas and the tumor distant cortex with respect to tumor (if available).
Time frame: 1 day
Sensitivity as percentage of actual positives and specificity as percentage of actual negatives of fluorescence detection at the biopsy level (if available).
Sensitivity as percentage of actual positives(True positive fraction/True positive fraction + False negative fraction)and specificity as percentage of actual negatives of fluorescence detection (True negative fraction/False positive fraction + True negative fraction) at the biopsy level (if available).
Time frame: 1 day
Safety
AEs during study period (Day 0 to Day 28), laboratory parameter, vital signs, EKG, pO2
Time frame: 28 days
Pharmacokinetic parameters of NPC-07 and active metabolite (Cmax, AUCt, tmax, t1/2）
Pharmacokinetic parameters of 5-ALA and PPVX (Cmax, AUCt, tmax, t1/2）
Time frame: 2 days
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nobelpharma